Melissa Pistilli

2 weeks ago | nasdaq.com | Georgia Williams |Melissa Pistilli

Uranium prices have surged since 2020, fueled by growing demand and optimism for the future. In February 2024, uranium reached its highest level in nearly two decades when values surpassed the US$100 level. Since then, prices have contracted, but remain historically high. Geopolitical tensions and trade concerns weighed on uranium prices in early 2025, pushing values below US$65 per pound for the first time since 2023. Now on the rebound spot U3O8 prices are holding at the US$70 level.

1 month ago | investingnews.com | Dean Belder |Melissa Pistilli

cobalt investinggraphite investinglithium investingmanganese investingnickel investingtantalum investingtin investingzinc investingvanadium investingtsxv:electsxv stockscopper investingCopper InvestingELEC:CASign up to get your FREE Corporate info Insights Growth strategies Upcoming projectsRoyalty company exclusively focused on clean energy metals, offering investors diversified exposure to the sector

1 month ago | investingnews.com | Melissa Pistilli |Danielle Adams

Equity Story Group Ltd (“Equity Story” or “the Company”, ASX:EQS) is pleased to announce that the Company has entered into a binding heads of agreement (HOA) to acquire the business and assets of Adelaide-based full-service financial advisory firm Baker Young Limited (Seller). .

1 month ago | investingnews.com | Melissa Pistilli

Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a chronic and debilitating immune-mediated inflammatory condition that can affect multiple organs.

1 month ago | investingnews.com | Diana Fernandez |Diana Fernández |Melissa Pistilli

EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: "This is an exciting time for Pfizer as we are already executing on and rigorously planning for an unprecedented number of anticipated new product and indication launches, most of which are expected to occur in the second half of 2023.